Innovative Light-Driven Technology Fuels Fermeate’s $2 Million Seed Round

Fermeate, a California-based startup focused on revolutionizing biomanufacturing through light-induced cell productivity, has successfully secured a $2 million seed round led by Newfund Capital.

This investment round, supported by various esteemed partners including SOSV, Ajinomoto Group Ventures, Ki Tua Fund, Heuristic Capital Partners, Momentum Capital, Plug and Play, Tesserkat Ventures, and Ag Startup Engine, aims to scale Fermeate’s groundbreaking technology, compatible with existing industrial fermentation systems.

Redefining Fermentation Efficiency

According to co-founder and CEO Dr. Kevin Xu, who started Fermeate in 2024 alongside Saurabh Malani, PhD, the fermentation industry has historically sought to expand capacity to cut costs. “We enable companies to enhance margins without the need for additional space,” Xu states.

The firm’s innovative technology allows for significant productivity enhancements—achieving up to a 200% increase in protein production within just six months—with a potential for up to a tenfold increase.

Benefits of Fermeate’s system include:

• Utilization of less expensive alternative feedstocks, such as transitioning from dextrose to dairy side streams.
• Higher protein yields achieved through non-toxic, light-based induction as opposed to chemical inducers like methanol.
• Shifts from fed-batch to more efficient semi-continuous processes.
• Prevention of genetic drift within production strains.

“Every major industrial transformation needs a foundational infrastructure layer. Fermeate’s optogenetic platform enhances the world’s current fermentation capabilities instead of replacing them; it’s exactly the type of technology Newfund has always supported,” said Henri Deshays, partner at Newfund Capital.

Enhancing Longevity in Cell Productivity

Dr. Xu highlights that despite advancements in strain engineering and optimization, highly developed microbes can still lose a significant amount of productivity during production. “We aim not only to boost productivity but also to sustain it longer,” he explained.

The technology utilizes light to control gene expression during fermentation, allowing real-time adjustments to cellular productivity. This leads to output improvements ranging from 60% to 300%, based on the results of recent collaborations, according to Xu.

Importantly, Fermeate can adapt existing stainless-steel fermenters at a fraction of the cost required for new bioreactor installations, streamlining the integration with existing operations through a light delivery system.

Mechanics of Light-Induced Productivity

Fermeate’s innovative process initiates with the introduction of light-sensitive proteins that can absorb wavelengths and trigger biological reactions. “It’s a dual-stage process,” explained Malani. “First, we incorporate a light-sensitive protein to make the strain controllable by light, and then we introduce a promoter to target specific enzymes.”

This control over gene activation through light exposure allows dynamic management of cellular behavior, fostering optimal protein production during fermentation. “By continuously optimizing the cellular assembly line, we minimize bottlenecks and maintain high cell productivity,” Xu asserted.

Navigating IP Challenges

Addressing intellectual property concerns, Xu clarified, “We can manipulate a company’s strain or guide them in doing it themselves, but we can work independently of their commercial strain.” Such flexibility allows collaborations based on R&D strains, enabling companies to evaluate the technology without jeopardizing their proprietary methods.

Future Outlook: Bridging Biomanufacturing and Manufacturing

Fermeate is exploring diverse business models while operating several lucrative projects. “We view biomanufacturing as another manufacturing form, necessitating efficiency in capital,” Xu stated. “The primary challenge lies in managing living systems. By establishing a reliable control layer, we can elevate biomanufacturing to the efficiency levels of other manufacturing processes.”

For more insights, explore the cutting-edge developments in the optogenetics sector, including fellow startups like Prolific Machines, concentrating on animal cells.

Further Reading:

• Vivici sees 30% boost in titers, yield, via cell productivity tech from Enduro Genetics
• Funding dip for alt protein fermentation signals shift from promise to proof
• 21st Bio on strains, scale, and the valley of death: Fixing precision fermentation’s weak links
• Future Food-Tech: Big ideas, hard truths, and the path to scale
• Driverless bioreactors? The future of biomanufacturing is lit, says Prolific Machines